Table 2.
Characteristics for cases and controls
| Patients’ characteristics | Cases | Controls | P-value |
|---|---|---|---|
| N = 446 | N = 4126 | ||
| Age (years) | 66.5 ± 12.8 | 68.1 ± 10.8 | 0.01 |
| Female sex (%) | 42.4 | 40.8 | 0.52 |
| Race (%) | |||
| Black | 6.0 | 4.1 | 0.16 |
| Caucasian | 84.5 | 86.1 | |
| Other | 9.4 | 9.8 | |
| BMI (kg/m2) | 27.8 ± 6.3 | 27.4 ± 6.3 | 0.29 |
| Smoking (%) | 15.5 | 14.1 | 0.41 |
| Co-morbidities (%) | |||
| Cardiovascular disease | 57.9 | 58.2 | 0.87 |
| Cerebrovascular disease | 17.7 | 16.3 | 0.46 |
| Chronic pulmonary disease | 32.5 | 30.0 | 0.27 |
| Chronic liver disease | 2.2 | 3.1 | 0.33 |
| Congestive heart failure | 37.4 | 37.8 | 0.89 |
| Diabetes | 57.9 | 53.1 | 0.05 |
| Hyperlipidemia | 58.3 | 58.7 | 0.87 |
| Hypertension | 94.8 | 94.1 | 0.52 |
| Malignancy | 17.7 | 16.7 | 0.60 |
| Peripheral vascular disease | 37.4 | 36.7 | 0.75 |
| ASA daily dose | |||
| Unexposed | 50.7 | 49.3 | 0.79 |
| 80-324 mg | 35.7 | 37.3 | |
| ≥ 325 mg | 13.7 | 13.4 | |
| Other medication use (%) | |||
| Anticoagulant | 28.9 | 21.2 | >0.001 |
| Antiplatelet | 11.0 | 11.8 | 0.63 |
| Laboratory data | |||
| Albumin (g/L) | 33.2 ± 6.6 | 33.9 ± 6.5 | 0.09 |
| eGFR (ml/min•1.73 m2) | 9.0 ± 3.7 | 9.1 ± 4.0 | 0.65 |
| Hemoglobin (g/L) | 10.2 ± 1.8 | 10.5 ± 1.8 | 0.01 |
Units conversion: Albumin, divide by 10 to convert g/L to g/dL; Hemoglobin, divide by 10 to convert g/L to g/dL
BMI body mass index; eGFR estimated glomerular filtration rate